Genmab A (GMAB) EBT Growth (3y) (2021 - 2026)
Powered by 
Analysis
Genmab A (GMAB) EBT Growth (3y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | 19.70% |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | -103.74% |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | 6.22% |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | 12.16% |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | 24.03% |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | 103.79% |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | 38.36% |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | -42.82% |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | - |
| 10 | Genmab A | 2.23 Bn | 728.64 Mn | 1.07 Bn | 22.34% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 22.34% |
| Mar 31, 2026 | -34.72% |
| Jun 30, 2025 | 38.01% |
| Sep 30, 2024 | -11.60% |
| Jun 30, 2024 | 48.70% |
| Mar 31, 2024 | -44.08% |
| Dec 31, 2023 | -112.41% |
| Sep 30, 2023 | 15,809.42% |
| Jun 30, 2023 | -28.83% |
| Mar 31, 2023 | -9.09% |
| Jun 30, 2022 | 178.40% |
| Dec 31, 2021 | -40.87% |
| Jun 30, 2021 | 63.44% |